Figure 1.

Pre-treatment regimens in patient cohort for HLA-A and B2M staining evaluation. This figure displays the distribution of pre-treatment regimens administered to the 213 patients prior to initiating the study’s trial protocol. The data was sourced from Clinical Study Reports by Roche, with the inclusion criteria limited to treatments received (i) before the first dose within the scope of the trial protocol, and (ii) designated either as premedication or as cancer therapy. The nomenclature for the treatments adheres to the conventions established by the Global Drug Safety Reporting (GDSR) system and the Medical Dictionary for Regulatory Activities (MedDRA).